Because EGFR and Kras mutations are two well-known oncogenic driver mutations in NSCLC patients, using the Oncomine database, we examined the KDM1A expression pattern based on EGFR and Kras mutation status in NSCLC, and found that regardless of mutation status, KDM1A was up-regulated in all NSCLCs. Here, KRAS is linked to non-small cell lung carcinoma.